Neoantigen Formation

Neoantigen Formation is the specific sequence of molecular events and selection criteria that determine whether a mutation-derived peptide actually becomes a functionally recognized neoantigen — one capable of being processed, displayed on a patient's particular MHC molecules, and recognized by an available T cell receptor — rather than remaining a silent genetic alteration with no immunological consequence. While tumor antigen generation described the range of molecular mechanisms (point mutation, frameshift, splicing, and others) that produce candidate antigenic peptides, neoantigen formation addresses the narrower, more demanding question of which of these candidates successfully clears every step required to become a genuine, immunologically active target.

The Multi-Step Filtering Process

Each of the probability terms in this relationship represents an independent filtering step at which a candidate mutation can fail to produce a functional neoantigen: the mutated gene must actually be transcribed and translated at meaningful levels within the tumor cell; the resulting protein must be processed by the proteasome into a peptide fragment of appropriate length; that peptide must bind with sufficient affinity to one of the patient's specific MHC allotypes (a step highly dependent on the individual's HLA genotype, since different HLA alleles bind different peptide sequences with very different affinities); and, finally, a T cell bearing a receptor capable of recognizing the resulting peptide-MHC complex must exist within the patient's T cell repertoire. Because these steps compound multiplicatively, only a small fraction of the total candidate mutations present in a typical tumor genome ultimately produce a functional neoantigen actually contributing to antitumor immunity.

HLA Binding Affinity as a Central Determinant

Because MHC molecules are highly polymorphic across the human population, and each specific HLA allele has a distinct binding groove favoring particular peptide sequences, the identical mutant peptide can be strongly presented in one patient's HLA context and essentially invisible in another's, meaning neoantigen formation is fundamentally an individualized process rather than a fixed property of the mutation itself. This individualization is why neoantigen prediction pipelines require patient-specific HLA typing as an essential input, and why the same tumor mutation profile can be expected to yield a different effective neoantigen repertoire in different patients.

Clonal Versus Subclonal Neoantigens

Neoantigens can be further distinguished by whether the underlying mutation is present in every tumor cell (clonal, arising early in tumor evolution before substantial subclonal diversification) or only in a subset of tumor cells (subclonal, arising later and present only in descendants of the cell in which it occurred). This distinction matters immunologically because a T cell response directed against a clonal neoantigen can, in principle, recognize and target every tumor cell within the lesion, while a response against a subclonal neoantigen can eliminate only the specific subpopulation carrying that mutation, leaving other subclones unaffected — a consideration directly relevant to the tumor heterogeneity themes discussed throughout this material, and one that has motivated preferential interest in targeting clonal neoantigens for therapeutic vaccine design specifically because of their more complete tumor coverage.

Foreignness and the Concept of Neoantigen Quality

Beyond simple presence on the cell surface, the degree to which a neoantigen's sequence differs from the corresponding normal self-peptide, and from the broader landscape of pathogen-derived peptides the immune system has previously encountered, influences how readily an available T cell receptor recognizes it, a property sometimes summarized as neoantigen quality. Neoantigens bearing greater sequence similarity to known microbial peptides have been associated with stronger, more readily elicited T cell responses in some studies, consistent with a model in which T cell receptors capable of recognizing structurally similar pathogen-derived peptides during prior infections are more likely to cross-react with a similarly shaped tumor neoantigen, providing one biological explanation for why neoantigen quantity alone (as approximated by tumor mutational burden) is an imperfect predictor of actual immunogenicity, and why neoantigen quality assessments increasingly supplement simple mutation counting in predicting immunotherapy responsiveness.

Clinical Application in Personalized Neoantigen Vaccines

The multi-step filtering logic described above directly informs the design of personalized neoantigen vaccines, an experimental therapeutic approach in which a patient's tumor mutations are sequenced, candidate peptides are computationally filtered through predicted expression, processing, and patient-specific HLA-binding steps, and the highest-confidence candidates are synthesized into a vaccine intended to boost the existing but often insufficiently robust T cell response against those specific neoantigens. The considerable attrition occurring at each filtering step described above is precisely why computational neoantigen prediction remains an active area of methodological refinement, since even modest improvements in predicting which candidates will actually clear the processing, presentation, and recognition steps can substantially affect which peptides are worth including in a resource-intensive personalized vaccine formulation.